胰岛β细胞功能障碍是2型糖尿病的基本病理生理特征。适当评估胰岛β细胞功能有利于更好地管理T2DM。保护胰岛β细胞功能对于延缓2型糖尿病的进展至关重要。因此,中国糖尿病学会和江苏省内分泌学会胰岛β细胞专家组组织专家起草了《2型糖尿病胰岛β细胞功能评估与保护临床专家共识》。“这一共识表明，β细胞功能可以使用基于血糖的方法或结合血糖和内源性胰岛素或C肽水平的方法进行临床评估。一些措施,包括体重减轻和早期持续控制血糖正常，能有效保护胰岛β细胞功能,和一些新开发的药物，如钠-葡萄糖协同转运蛋白-2抑制剂和胰高血糖素样肽-1受体激动剂，可以改善胰岛β细胞功能，独立于血糖控制。
Islet β-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appropriate assessment of islet β-cell function is beneficial to better management of T2DM. Protecting islet β-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the \"Clinical expert
consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus.\" This
consensus suggests that β-cell function can be clinically assessed using blood glucose-based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control.
